Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 7/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | TYMS | P04818 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7201324 | 0.85 | TK1 (0.60) | TK1POLBTYMS | |
| SCHEMBL25756099 | 0.85 | TK1 (0.60) | TK1POLBTYMS | |
| SCHEMBL25752637 | 0.85 | TK1 (0.60) | TK1POLBTYMS | |
| SCHEMBL25700727 | 0.85 | TK1 (0.60) | TK1POLBTYMS | |
| SCHEMBL9011028 | 0.85 | TK1 (0.53) | TK1POLB | |
| SCHEMBL6445763 | 0.83 | DNPH1 (0.42) | TK1 | |
| SCHEMBL7525577 | 0.82 | TK1 (0.61) | TK1POLBTYMS | |
| SCHEMBL27984187 | 0.82 | TK1 (0.61) | TK1POLBTYMS | |
| SCHEMBL25752530 | 0.81 | TK1 (0.70) | TK1POLB | |
| SCHEMBL820020 | 0.80 | TYMS (0.51) | TK1POLBTYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427470-B1 | METHOD FOR THE SOLID PHASE-BASED PRODUCTION OF PHOSPHATE-BRIDGED NUCLEOSIDE CONJUGATES | UNIVERSITÄT HAMBURG (DE) | 2014-08-20 | — | — | EP | disclosed |
| US-8742094-B2 | Method for the solid phase-based production of phosphate-bridged nucleoside conjugates | UNIVERSITAET HAMBURG (DE) | 2014-06-03 | — | — | US | disclosed |
| US-20120116067-A1 | METHOD FOR THE SOLID PHASE-BASED PRODUCTION OF PHOSPHATE-BRIDGED NUCLEOSIDE CONJUGATES | UNIVERSITAET HAMBURG (DE) | 2012-05-10 | — | — | US | disclosed |
| EP-2427470-A1 | METHOD FOR THE SOLID PHASE-BASED PRODUCTION OF PHOSPHATE-BRIDGED NUCLEOSIDE CONJUGATES | Universität Hamburg (DE) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010127666-A1 | METHOD FOR THE SOLID PHASE-BASED PRODUCTION OF PHOSPHATE-BRIDGED NUCLEOSIDE CONJUGATES | UNIVERSITÄT HAMBURG (DE) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120116067-A1 | METHOD FOR THE SOLID PHASE-BASED PRODUCTION OF PHOSPHATE-BRIDGED NUCLEOSIDE CONJUGATES | PNP, TYMP, DPYD | TK1 54/4885POLB 189/4885TYMS 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.